Data Sheet (Cat.No.T14684)

TargetMol

BMS-986120

Chemical Properties



CAS No. : 1478712-37-6

Formula: C23H23N5O5S2

Molecular Weight: 513.59

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BMS-986120 is a first-in-class oral, reversible protease-activated receptor 4 (PAR4) antagonist with IC50s of 9.5 nM in human blood and 2.1 nM in monkey blood, exhibiting potent and selective antiplatelet effects[1][2].
Targets(IC50)	Others,Protease-activated Receptor
In vitro	BMS-986120 has high binding affinity to PAR4 expressed on HEK293 cells. And it inhibition of PAR4-induced calcium mobilization with an IC50 of 0.56 nM[3].
In vivo	BMS, administered at dosages of 0.2, 0.5, and 1 mg/kg, decreases tail withdrawal (TW) by 35±5, 49±4, and 83±4%, respectively. In monkeys, a 1 mg/kg dose of BMS shows no inhibition of platelet aggregation (PA) triggered by PAR1-AP, ADP, and collagen, indicating selectivity. The maximum increases observed in kaolin bleeding time (KBT) and mepacrine bleeding time (MBT) are limited to 2.2-fold and 1.8-fold, respectively[1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9471 mL	9.7354 mL	19.4708 mL
5 mM	0.3894 mL	1.9471 mL	3.8942 mL
10 mM	0.1947 mL	0.9735 mL	1.9471 mL
50 mM	0.0389 mL	0.1947 mL	0.3894 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Pancras C Wong, et al. Abstract 175: A Novel Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986120, Inhibits Arterial Thrombosis With Limited Impact on Hemostasis in Cynomolgus Monkeys. Stroke. 2018;47:A175.

Wilson SJ, et al. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex VivoThrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456.

Wong PC, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med. 2017 Jan 4;9(371).

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481